Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)

Trial Profile

Phase II Open 24 Weeks Study to Evaluate Effect and Safety of Tocilizumab as the First Line Therapy in Subjects With Polymyalgia Rheumatica (PMR)

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Jun 2019

At a glance

  • Drugs Tocilizumab (Primary) ; Corticosteroid
  • Indications Polymyalgia rheumatica
  • Focus Therapeutic Use
  • Acronyms TENOR
  • Most Recent Events

    • 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
    • 15 Mar 2019 Results of post-hoc analysis published in The Journal of Rheumatology.
    • 31 Aug 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top